Ellicott City, M.D., July 14, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests and voice of clinical research sites, today announced that it is accepting submissions for its annual Site Patient Recruitment Innovation Award (SPRIA), which recognizes sites that employ innovative strategies to achieve enrollment success. The winner will be recognized at SCRS’ Global Site Solutions Summit, which takes place October 8-11, at Amelia Island, FL.
In judging submissions, emphasis is placed on innovative patient-directed initiatives that are unique, effective and take into account the response of the campaign. All sites are invited to submit their recruitment plans for the SPRIA, which was launched in 2014 to great success.
An independent judging panel will select three finalists from the submissions. The finalists will be invited to attend the Site Solutions Summit with a complimentary registration. At the summit, the finalists will present their plans to an audience of executives from sites, sponsors, and CROs. The judging panel then will determine the winner. Sites deserving Honorary Mention for innovation in patient recruitment will be honored with a poster presentation in the SCRS SPRIA Gallery at the Summit. The SPRIA is sponsored by Acurian.
Nominations forms can be downloaded on the Global Site Solutions Summit website. Completed form should be sent to SPRIA@myscrs.org by July 31, 2015.
DM Clinical Research won last year’s inaugural SPRIA .
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.